Arcellx Appoints Michelle Gilson as Chief Financial Officer

FOSTER Town, Calif., Might 23, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology business reimagining mobile therapy as a result of the advancement of ground breaking immunotherapies for sufferers with cancer and other incurable diseases, these days introduced the appointment of Michelle Gilson as Main Money Officer. Ms. Gilson joins Arcellx from Canaccord Genuity, where by most not long ago she served as Running Director and Senior Equity Exploration Analyst covering biotechnology companies. Ms. Gilson will oversee the firm’s finance purpose and will enjoy a key job in all round company tactic.

“Michelle’s eyesight, leadership, and practical experience as a analysis analyst, which bundled covering corporations in the oncology area, will be an a must have addition to the existing breadth of expertise on our management team,” claimed Rami Elghandour, Arcellx’s Chairman and Main Executive Officer. “Michelle brings a depth of expertise in cash marketplaces and biotechnology and represents the values we look for in our leaders that manufactured her an perfect healthy for Arcellx. On behalf of our organization and Board of Administrators, we welcome Michelle to our workforce. I search ahead to the impactful job I know she will engage in as we go on in the direction of our mission of bringing our mobile therapy to marketplace to aid as lots of patients as possible.”

Most a short while ago, Ms. Gilson served as a Managing Director and Senior Equity Analysis Analyst at Canaccord Genuity, covering biotechnology providers. Prior to joining Canaccord, Ms. Gilson held biotechnology fairness investigation roles at Jefferies, LLC Instinet, LLC (Nomura Securities) Oppenheimer & Co. Inc. and Goldman Sachs. Ms. Gilson attained her B.S. in Enterprise Administration from the University of Southern California.

About Arcellx, Inc.

Arcellx, Inc. is a scientific-stage biotechnology corporation reimagining mobile remedy by engineering progressive immunotherapies for patients with cancer and other incurable diseases. Arcellx thinks that cell therapies are a single of the forward pillars of drugs and Arcellx’s mission is to progress humanity by creating cell therapies that are safer, extra productive, and a lot more broadly accessible. Arcellx’s lead merchandise prospect, CART-ddBCMA, is getting developed for the remedy of relapsed or refractory numerous myeloma (r/r MM) in an ongoing Stage 1 analyze. CART-ddBCMA has been granted Rapid Monitor, Orphan Drug, and Regenerative Medicine Sophisticated Therapy designations by the U.S. Food stuff and Drug Administration.

Arcellx is also advancing its dosable and controllable Car or truck-T treatment, ARC-SparX, by means of two plans: a Section 1 research of ACLX-001 for r/r MM, initiated in the second quarter of 2022 and ACLX-002 in relapsed or refractory acute myeloid leukemia and large-threat myelodysplastic syndrome, expected to enter the clinic in the 2nd fifty percent of 2022.

Visit www.arcellx.com for much more information and facts.

Forward-on the lookout Statements

This push launch consists of ahead-seeking statements within just the meaning of Area 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. All statements in this push release that are not purely historic are forward-seeking statements. The ahead-on the lookout statements contained herein are centered upon Arcellx’s current anticipations and contain assumptions that might never ever materialize or might confirm to be incorrect. These forward-on the lookout statements are neither promises nor assures and are topic to a wide range of dangers and uncertainties, including hazards that may possibly be located in the part entitled “Danger Things” in paperwork that Arcellx documents from time to time with the Securities and Exchange Commission. These forward-wanting statements are manufactured as of the day of this push release, and Arcellx assumes no obligation to update or revise any forward-on the lookout statements, whether as a final result of new facts, long term situations or otherwise, except as essential by legislation.

Trader Speak to:

Myesha Lacy

Arcellx, Inc.

[email protected]

510-418-2412

Media Contact

Andrea Cohen

Sam Brown Inc.

[email protected]

917-209-7163

Watch authentic articles to obtain multimedia:https://www.prnewswire.com/news-releases/arcellx-appoints-michelle-gilson-as-chief-economic-officer-301551505.html